Download Files:
Remogliflozin etabonate
$110 – $1,080
Products Details
Product Description
– Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models[1].
Web ID
– HY-14945
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C26H38N2O9
References
– [1]Yoshikazu Fujimori, et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. J Pharmacol Exp Ther. 2008 Oct;327(1):268-76.
CAS Number
– 442201-24-3
Molecular Weight
– 522.59
Compound Purity
– 99.81
SMILES
– CCOC(OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC2=NN(C(C)C)C(C)=C2CC3=CC=C(OC(C)C)C=C3)=O
Clinical Information
– Phase 2
Research Area
– Metabolic Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– SGLT
Isoform
– SGLT1;SGLT2
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
